Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047122 | 1.00 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL731077 | 0.99 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL27734590 | 0.99 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL2044501 | 0.85 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL2044500 | 0.85 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL732930 | 0.84 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL2431239 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTABCC4CYP3A4 | |
| SCHEMBL18882155 | 0.78 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTCYP3A4RECQL | |
| SCHEMBL30170128 | 0.77 | CNR1 (0.36) | RECQLFAAHMEN1KMT2A | |
| SCHEMBL13389921 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTABCC4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ALDH1A1 623/4885LMNA 3735/4885MAPT 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.